Rivaroxaban: Population Pharmacokinetic Analyses in Patients Treated for Acute Deep-Vein Thrombosis and Exposure Simulations in Patients with Atrial Fibrillation Treated for Stroke Prevention

Author： Mueck Wolfgang  

Publisher： Adis International

ISSN： 0312-5963

Source： Clinical Pharmacokinetics, Vol.50, Iss.10, 2011-10, pp. : 675-686

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Guidelines for Stroke Prevention in Patients with Atrial Fibrillation

By Howard P.A.  

Drugs, Vol. 58, Iss. 6, 1999-12 ,pp. : 997-1009

Adis International

Access to resources Recommend Favorite

Risk of intracranial haemorrhage in patients with atrial fibrillation treated with novel oral anticoagulants: testing the equivalence margins between dabigratran, rivaroxaban and apixaban

By Messori Andrea   Maratea Dario   Fadda Valeria   Trippoli Sabrina  

European Journal of Clinical Pharmacology, Vol. 70, Iss. 4, 2014-04 ,pp. : 505-506

Springer Publishing Company

Access to resources Recommend Favorite

Secondary Prevention of Stroke in Patients with Nonvalvular Atrial Fibrillation: Optimal Intensity of Anticoagulation

By Yasaka M.   Yamaguchi T.  

CNS Drugs, Vol. 15, Iss. 8, 2001-01 ,pp. : 623-631

Adis International

Access to resources Recommend Favorite

Spotlight on Dabigatran Etexilate in the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation†

By Garnock-Jones Karly P.  

Drugs & Aging, Vol. 28, Iss. 5, 2011-05 ,pp. : 415-419

Adis International

Access to resources Recommend Favorite

Dabigatran Etexilate: A Review of its Use in the Prevention of Stroke and Systemic Embolism in Patients with Atrial Fibrillation

By Garnock-Jones Karly P.  

American Journal of Cardiovascular Drugs, Vol. 11, Iss. 1, 2011-02 ,pp. : 57-72

Adis International

Access to resources Recommend Favorite